Capstone Investment Advisors
LCTX icon

Capstone Investment Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Capstone Investment Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-21,090
Closed -$50K – 1794
2021
Q1 		$50K Sell
21,090
-106,080
-83% -$255K ﹤0.01% 1604
2020
Q4 		$224K Buy
+127,170
New +$178K ﹤0.01% 1433

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Capstone Investment Advisors's LCTX Position: Q2 2021 in Review

Capstone Investment Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q2 2021, closing a stake of 21,090 shares — an estimated $50K sold.

Capstone Investment Advisors first reported a position in LCTX in Q4 2020 and held it in 2 quarters. The position peaked at $224K in Q4 2020. 115 funds tracked by Wall St. Rank hold LCTX as of Q2 2021.

  • Capstone Investment Advisors reported no remaining Lineage Cell Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 21,090 Lineage Cell Therapeutics shares in Q2 2021, an estimated $50K.
  • Capstone Investment Advisors first reported a position in Lineage Cell Therapeutics in Q4 2020 and held it in 2 quarters.
  • Capstone Investment Advisors's Lineage Cell Therapeutics position peaked at $224K in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2021.

Based on Capstone Investment Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.